422 related articles for article (PubMed ID: 26757980)
21. PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia.
Yamamoto T; Isomura M; Xu Y; Liang J; Yagasaki H; Kamachi Y; Kudo K; Kiyoi H; Naoe T; Kojma S
Leuk Res; 2006 Sep; 30(9):1085-9. PubMed ID: 16533526
[TBL] [Abstract][Full Text] [Related]
22. Acute lymphoblastic leukemia in the context of RASopathies.
Cavé H; Caye A; Strullu M; Aladjidi N; Vignal C; Ferster A; Méchinaud F; Domenech C; Pierri F; Contet A; Cacheux V; Irving J; Kratz C; Clavel J; Verloes A
Eur J Med Genet; 2016 Mar; 59(3):173-8. PubMed ID: 26855057
[TBL] [Abstract][Full Text] [Related]
23. Malignant diseases in Noonan syndrome and related disorders.
Hasle H
Horm Res; 2009 Dec; 72 Suppl 2():8-14. PubMed ID: 20029231
[TBL] [Abstract][Full Text] [Related]
24. Juvenile myelomonocytic leukemia-associated variants are associated with neo-natal lethal Noonan syndrome.
Mason-Suares H; Toledo D; Gekas J; Lafferty KA; Meeks N; Pacheco MC; Sharpe D; Mullen TE; Lebo MS
Eur J Hum Genet; 2017 Apr; 25(4):509-511. PubMed ID: 28098151
[TBL] [Abstract][Full Text] [Related]
25. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.
Lipka DB; Witte T; Toth R; Yang J; Wiesenfarth M; Nöllke P; Fischer A; Brocks D; Gu Z; Park J; Strahm B; Wlodarski M; Yoshimi A; Claus R; Lübbert M; Busch H; Boerries M; Hartmann M; Schönung M; Kilik U; Langstein J; Wierzbinska JA; Pabst C; Garg S; Catalá A; De Moerloose B; Dworzak M; Hasle H; Locatelli F; Masetti R; Schmugge M; Smith O; Stary J; Ussowicz M; van den Heuvel-Eibrink MM; Assenov Y; Schlesner M; Niemeyer C; Flotho C; Plass C
Nat Commun; 2017 Dec; 8(1):2126. PubMed ID: 29259247
[TBL] [Abstract][Full Text] [Related]
26. [Juvenile myelomonocytic leukemias].
Lachenaud J; Strullu M; Baruchel A; Cavé H
Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
[TBL] [Abstract][Full Text] [Related]
27. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
[TBL] [Abstract][Full Text] [Related]
28. Proteomic Analysis of an Induced Pluripotent Stem Cell Model Reveals Strategies to Treat Juvenile Myelomonocytic Leukemia.
Pearson S; Guo B; Pierce A; Azadbakht N; Brazzatti JA; Patassini S; Mulero-Navarro S; Meyer S; Flotho C; Gelb BD; Whetton AD
J Proteome Res; 2020 Jan; 19(1):194-203. PubMed ID: 31657576
[TBL] [Abstract][Full Text] [Related]
29. Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment.
Dong L; Yu WM; Zheng H; Loh ML; Bunting ST; Pauly M; Huang G; Zhou M; Broxmeyer HE; Scadden DT; Qu CK
Nature; 2016 Nov; 539(7628):304-308. PubMed ID: 27783593
[TBL] [Abstract][Full Text] [Related]
30. Acute lymphoblastic leukemia developing in a patient with Noonan syndrome harboring a PTPN11 germline mutation.
Sakamoto K; Imamura T; Asai D; Goto-Kawashima S; Yoshida H; Fujiki A; Furutani A; Ishida H; Aoki Y; Hosoi H
J Pediatr Hematol Oncol; 2014 Mar; 36(2):e136-9. PubMed ID: 24072241
[TBL] [Abstract][Full Text] [Related]
31. Noonan syndrome and related disorders: genetics and pathogenesis.
Tartaglia M; Gelb BD
Annu Rev Genomics Hum Genet; 2005; 6():45-68. PubMed ID: 16124853
[TBL] [Abstract][Full Text] [Related]
32. PTPN11 and KRAS gene analysis in patients with Noonan and Noonan-like syndromes.
Brasil AS; Pereira AC; Wanderley LT; Kim CA; Malaquias AC; Jorge AA; Krieger JE; Bertola DR
Genet Test Mol Biomarkers; 2010 Jun; 14(3):425-32. PubMed ID: 20578946
[TBL] [Abstract][Full Text] [Related]
33. Juvenile myelomonocytic leukemia in a 16-year-old with Noonan syndrome: case report.
Ortiz MV; Skoda-Smith S; Rauen KA; Allan RW; Slayton WB
J Pediatr Hematol Oncol; 2012 Oct; 34(7):569-72. PubMed ID: 22510777
[TBL] [Abstract][Full Text] [Related]
34. Transient juvenile myelomonocytic leukemia in the setting of PTPN11 mutation and Noonan syndrome with secondary development of monosomy 7.
O'Halloran K; Ritchey AK; Djokic M; Friehling E
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28084675
[TBL] [Abstract][Full Text] [Related]
35. Clonal duplication of a germline PTPN11 mutation due to acquired uniparental disomy in acute lymphoblastic leukemia blasts from a patient with Noonan syndrome.
Karow A; Steinemann D; Göhring G; Hasle H; Greiner J; Harila-Saari A; Flotho C; Zenker M; Schlegelberger B; Niemeyer CM; Kratz CP
Leukemia; 2007 Jun; 21(6):1303-5. PubMed ID: 17361219
[No Abstract] [Full Text] [Related]
36. Cardiovascular disease in Noonan syndrome.
Pierpont ME; Digilio MC
Curr Opin Pediatr; 2018 Oct; 30(5):601-608. PubMed ID: 30024444
[TBL] [Abstract][Full Text] [Related]
37. Gene mutations in the Ras pathway and the prognostic implication in Korean patients with juvenile myelomonocytic leukemia.
Park HD; Lee SH; Sung KW; Koo HH; Jung NG; Cho B; Kim HK; Park IA; Lee KO; Ki CS; Kim SH; Yoo KH; Kim HJ
Ann Hematol; 2012 Apr; 91(4):511-7. PubMed ID: 21901340
[TBL] [Abstract][Full Text] [Related]
38. Contribution of RIT1 mutations to the pathogenesis of Noonan syndrome: four new cases and further evidence of heterogeneity.
Gos M; Fahiminiya S; Poznański J; Klapecki J; Obersztyn E; Piotrowicz M; Wierzba J; Posmyk R; Bal J; Majewski J
Am J Med Genet A; 2014 Sep; 164A(9):2310-6. PubMed ID: 24939608
[No Abstract] [Full Text] [Related]
39. Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes.
Kratz CP; Franke L; Peters H; Kohlschmidt N; Kazmierczak B; Finckh U; Bier A; Eichhorn B; Blank C; Kraus C; Kohlhase J; Pauli S; Wildhardt G; Kutsche K; Auber B; Christmann A; Bachmann N; Mitter D; Cremer FW; Mayer K; Daumer-Haas C; Nevinny-Stickel-Hinzpeter C; Oeffner F; Schlüter G; Gencik M; Überlacker B; Lissewski C; Schanze I; Greene MH; Spix C; Zenker M
Br J Cancer; 2015 Apr; 112(8):1392-7. PubMed ID: 25742478
[TBL] [Abstract][Full Text] [Related]
40. RIT1 oncoproteins escape LZTR1-mediated proteolysis.
Castel P; Cheng A; Cuevas-Navarro A; Everman DB; Papageorge AG; Simanshu DK; Tankka A; Galeas J; Urisman A; McCormick F
Science; 2019 Mar; 363(6432):1226-1230. PubMed ID: 30872527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
